Study of fucoidans as natural biomolecules for therapeutical applications in osteoarthritis

Abstract

Osteoarthritis (OA) is the most prevalent articular chronic disease. Although, to date there is no cure for OA. Fucoidans, one of the main therapeutic components of brown algae, have emerged as promising molecules in OA treatment. However, the variability between fucoidans makes difficult the pursuit of the most suitable candidate to target specific pathological processes. By an in vitro experimental approach in chondrocytes and fibroblast-like synoviocytes, we observed that chemical composition of fucoidan, and specifically the phlorotannin content and the ratio sulfate:fucose, seems critically relevant for its biological activity. Nonetheless, other factors like concentration and molecular weight of the fucoidan may influence on its beneficial effects. Additionally, a cell-type dependent response was also detected. Thus, our results shed light on the potential use of fucoidans as natural molecules in the treatment of key pathological processes in the joint that favor the development of rheumatic disorders as OA.

Keywords: Antimycin A (PubChem CID: 14957); Dextran (PubChem CID: 4125253); Fucoidan (PubChem CID: 92023653); Fucose (PubChem CID: 3034656); Fucus vesiculosus fucoidan; Galactose (PubChem CID: 6036); Glucose (PubChem CID: 5793); Interleukin-1 beta (PubChem CID: 123872); Macrocystis pyrifera fucoidan; Osteoarthritic chondrocytes; Osteoarthritis; Phloroglucinol (PubChem CID: 359); Potassium sulfate (PubChem CID: 24507); Synovial fibroblasts; Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) (PubChem CID: 40634); Undaria pinnatifida fucoidan.